1. Home
  2. YETI vs IMNM Comparison

YETI vs IMNM Comparison

Compare YETI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo YETI Holdings Inc.

YETI

YETI Holdings Inc.

N/A

Current Price

$41.26

Market Cap

3.1B

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$20.84

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YETI
IMNM
Founded
2006
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.5B
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
YETI
IMNM
Price
$41.26
$20.84
Analyst Decision
Buy
Strong Buy
Analyst Count
16
15
Target Price
★ $54.93
$36.00
AVG Volume (30 Days)
★ 1.5M
1.0M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 51.40
EPS
★ 1.06
N/A
Revenue
★ $1,868,494,000.00
$6,941,000.00
Revenue This Year
$7.64
N/A
Revenue Next Year
$7.09
$17,534.68
P/E Ratio
$39.87
★ N/A
Revenue Growth
★ 2.11
N/A
52 Week Low
$31.66
$11.55
52 Week High
$53.99
$30.06

Technical Indicators

Market Signals
Indicator
YETI
IMNM
Relative Strength Index (RSI) 42.36 32.99
Support Level $38.75 $19.39
Resistance Level $43.39 $23.25
Average True Range (ATR) 1.56 1.08
MACD 0.22 -0.35
Stochastic Oscillator 31.30 11.87

Price Performance

Historical Comparison
YETI
IMNM

About YETI YETI Holdings Inc.

YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: